Charles River Laboratories International (NYSE:CRL) Reaches New 52-Week Low - What's Next?

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report)'s stock price reached a new 52-week low during trading on Wednesday . The stock traded as low as $175.61 and last traded at $178.38, with a volume of 1867915 shares trading hands. The stock had previously closed at $190.14.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Robert W. Baird decreased their price target on Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating for the company in a report on Friday, September 20th. Citigroup cut Charles River Laboratories International from a "neutral" rating to a "sell" rating and decreased their target price for the stock from $215.00 to $175.00 in a research note on Tuesday, October 1st. TD Cowen increased their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research note on Monday, November 11th. William Blair reissued an "outperform" rating on shares of Charles River Laboratories International in a report on Tuesday. Finally, UBS Group restated a "neutral" rating and issued a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday. Three investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Charles River Laboratories International has a consensus rating of "Hold" and a consensus price target of $209.00.

Charles River Laboratories International Stock Down 1.2 %

The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The firm's 50 day moving average price is $191.67 and its two-hundred day moving average price is $198.72. The firm has a market cap of $8.37 billion, a price-to-earnings ratio of 20.50, a P/E/G ratio of 6.62 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same period last year, the business posted $2.72 EPS. The company's revenue was down 1.6% on a year-over-year basis. As a group, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares of the company's stock, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.30% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CRL. Empirical Finance LLC grew its holdings in shares of Charles River Laboratories International by 4.2% during the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company's stock worth $258,000 after buying an additional 53 shares in the last quarter. American Trust boosted its position in Charles River Laboratories International by 5.9% during the second quarter. American Trust now owns 976 shares of the medical research company's stock worth $202,000 after acquiring an additional 54 shares during the last quarter. OLD National Bancorp IN grew its stake in Charles River Laboratories International by 3.1% in the 3rd quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company's stock worth $392,000 after acquiring an additional 59 shares during the period. Fiduciary Financial Group LLC raised its holdings in Charles River Laboratories International by 3.9% in the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock valued at $310,000 after acquiring an additional 63 shares during the last quarter. Finally, Pinnacle Bancorp Inc. lifted its stake in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after purchasing an additional 65 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).